Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

NCT02169609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Neoplasm, Residual
Effects of Immunotherapy

Interventions

DRUG: Dinutuximab. Immunotherapy

Sponsor

Fundació Sant Joan de Déu